Working... Menu

EUS-Guided Cryothermal Ablation in Patients With Stage III Pancreatic Adenocarcinoma (HybridTherm Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02336672
Recruitment Status : Recruiting
First Posted : January 13, 2015
Last Update Posted : June 13, 2018
Information provided by (Responsible Party):
Paolo Giorgio Arcidiacono, MD, IRCCS San Raffaele

Brief Summary:
In patients with locally advanced tumour, neoadjuvant treatment has been proposed in various modalities as a way to decrease size and downstage the tumour leading to a re-sectable disease. The HybridTherm probe (HTP), (ERBE Elektromedizin GmbH, Tübingen, Germany) combines bipolar RF-ablation with cryogenic induced cooling. A bipolar radiofrequency system creates ablation with less collateral thermal damage than standard monopolar systems but with the trade-off to lose overall efficiency.

Condition or disease Intervention/treatment Phase
Pancreatic Adenocarcinoma Non-resectable Device: Cryothermal ablation Not Applicable

Detailed Description:
About 40% of patients with pancreatic cancer have no metastasis at the moment of diagnosis, but in 20% of patients surgery is not feasible due to vascular invasion or poor general conditions. These patients with stage III pancreatic cancer (locally advanced or borderline resectable) may benefit from neoadjuvant chemotherapy or chemoradiotherapy. The HybridTherm probe is a new, minimally invasive device that can be safely applied under EUS guidance to locally ablate the pancreatic tissue adding a local efficacy to the systemic activity offered by chemotherapy and could give these patients a bigger chance of survival. The present study is an interventional randomized controlled phase II/III trial (device), that assigns patients into two groups: patients receiving standard chemotherapy alone and those receiving chemotherapy plus EUS-guided HybridTherm ablation. The randomization is performed at the time of EUS diagnosis and staging.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: EUS-Guided Cryothermal Ablation in Patients With Stage III (Locally Advanced and Borderline Resectable) Pancreatic Adenocarcinoma
Actual Study Start Date : November 11, 2014
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : June 2019

Arm Intervention/treatment
No Intervention: Group A Chemotherapy
Patients receiving chemotherapy alone. These patients start standard chemotherapy right after the oncologist's evaluation according to accepted Guidelines of the Italian Association of Medical Oncologists (AIOM). Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
Experimental: Group B Chemotherapy + HybridTherm
Patients receiving chemotherapy plus EUS-guided Cryothermal Ablation with HybridTherm probe. These patients are first treated by cryothermal ablation and one week after they start with chemotherapy. Cryothermal ablation can be performed up to three times, with interval of 4 +/- 1 weeks. Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
Device: Cryothermal ablation
Procedures are performed with patients sedated by anaesthesiologists. Device setting and application time are set and recorded on a computer, that analyzes the changes of the tissue's properties. The setting of the maximal application time is based on the results of our previously described ex-vivo and in-vivo studies and is adjusted to the tumour's size, thus ensuring a reduction of procedure-related complications. Application of Power Doppler makes the procedure safer. The HybridTherm probe is guided under real-time EUS into the tumour, and the success of its placement is an index of the treatment's feasibility. The system analyzes the effects on the tissue and EUS records the changes of the tissue, the growing edema around the treated area, and the tissue devitalization.
Other Name: HybridTherm probe

Primary Outcome Measures :
  1. Progression free survival [ Time Frame: 6-months after therapy onset ]

    To demonstrate the efficacy of the HybridTherm probe in the control of the tumour progression in terms of progression-free survival, measured at 6-month after ther-apy onset (PFS-6). PFS-6 takes in consideration the tumor growth in relation to the volume/size evaluated as a difference between the previous and the current examination. In practice, it is the time interval between the enrolment of the patient and the first radiological evidence of tumor progression.

    For patients who were resected (R0 and R1) the PFS is the time until the first radio-logical evidence of tumor recurrence, regardless size.

    For not resected patients the PFS is the time until the first radiological evidence of a growth of the lesion > 20% in comparison to the previous exam.

Secondary Outcome Measures :
  1. Response to treatment [ Time Frame: At 2 and 4 months after the treatment ]
    Evaluated by the radiological response to the treatment calculated on the differ-ences of radiological images (DW-MRI) before treatment onset and after two and four month of treatment

  2. Evaluation of cell disruption / necrosis of the treated area [ Time Frame: At 2 and 4 months after the treatment ]
    Measured with the Apparent Diffusion Coefficient in the dw-MRI which will be per-formed at the time of patients' enrolment, after HTP treatment (Group B) and after two and four month of treatment.

  3. Rate of resectability [ Time Frame: After 4 months pf treatment ]
    Evaluated by the number of resectable patients after four month of treatment

  4. R0 Resection Rate: [ Time Frame: After surgical resection ]
    Evaluated by the number of R0 resections for those patients who were submitted to sur-gery (see Rate of resectability) on the basis of the pathologists finding

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • pathological diagnosis
  • patients with borderline resectable/locally advanced pancreatic adenocarcinoma;
  • patients no previously treated with neoadjuvant treatments, irrespective of the regimen
  • age >18 years; ≤ 80
  • genders eligible for study: both
  • patients who can express their consent
  • Karnofsky Performance status >70;
  • Life expectancy >6 months.
  • PLT>100000/mcl; INR<1.5.
  • adequate renal function with a creatinine threshold
  • adequate bone marrow function (WBC ≥3500)

Exclusion Criteria:

  • pregnancy
  • acute pancreatitis
  • patients having distant metastasis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02336672

Layout table for location contacts
Contact: Paolo Giorgio Arcidiacono, MD FASGE +39 02-26436306

Layout table for location information
Ospedale San Raffaele Irccs Recruiting
Milan, MI, Italy, 20132
Contact: Paolo Giorgio Arcidiacono, MD    +39-02-26435607   
Sponsors and Collaborators
IRCCS San Raffaele
Layout table for investigator information
Principal Investigator: Paolo Giorgio Arcidiacono, MF FASGE IRCCS San Raffaele

Layout table for additonal information
Responsible Party: Paolo Giorgio Arcidiacono, MD, Chief of GI Endoscopy Unit, IRCCS San Raffaele Identifier: NCT02336672     History of Changes
Other Study ID Numbers: HTP/2014
First Posted: January 13, 2015    Key Record Dates
Last Update Posted: June 13, 2018
Last Verified: June 2018

Keywords provided by Paolo Giorgio Arcidiacono, MD, IRCCS San Raffaele:
Pancreatic adenocarcinoma

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type